Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Total Current Liabilities (2023 - 2025)

Historic Total Current Liabilities for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $11.1 million.

  • Artiva Biotherapeutics' Total Current Liabilities fell 1634.82% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 1634.82%. This contributed to the annual value of $12.3 million for FY2024, which is 21.26% up from last year.
  • As of Q3 2025, Artiva Biotherapeutics' Total Current Liabilities stood at $11.1 million, which was down 1634.82% from $10.8 million recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Total Current Liabilities high stood at $13.3 million for Q3 2024, and its period low was $10.8 million during Q2 2025.
  • For the 3-year period, Artiva Biotherapeutics' Total Current Liabilities averaged around $11.8 million, with its median value being $12.2 million (2025).
  • As far as peak fluctuations go, Artiva Biotherapeutics' Total Current Liabilities rose by 21.26% in 2024, and later plummeted by 1634.82% in 2025.
  • Artiva Biotherapeutics' Total Current Liabilities (Quarter) stood at $12.2 million in 2023, then grew by 0.21% to $12.3 million in 2024, then decreased by 9.25% to $11.1 million in 2025.
  • Its Total Current Liabilities stands at $11.1 million for Q3 2025, versus $10.8 million for Q2 2025 and $12.2 million for Q1 2025.